People | October 13, 2025
Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Medico Remedies receives order worth US$ 1,781,000
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
India currently hosts more than 10,075 biotech startups
Miels will formally assume the role on January 1, 2026
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
Subscribe To Our Newsletter & Stay Updated
